Meeting NewsVideo

VIDEO: Bimatoprost SR implant shows sustained IOP lowering after three treatments

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.

    See more from American Society of Cataract and Refractive Surgery Meeting